| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | President and CEO
1 company
Thomas Andrew Crockett last filed a Form 4 in February 2024, as CEO at KALV. Thomas Andrew Crockett's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Thomas Andrew Crockett's trades have earned a strong insider score of 72/100 across 17 rated trades. Over a 12-month horizon, 70.6% of those trades were profitable, with an average 12-month return of +19.3%.
At the last filing, the largest reported position was 211,203 shares of KALV. The KALV filings lean toward selling, a net 323,156 shares.
Thomas Andrew Crockett has 39 Form 4 filings on record from November 2016 to February 2024, all as CEO at KalVista Pharmaceuticals (KALV), 2016–2024.
The 70 reported transactions were 44 open-market sales, 12 option or other derivative awards, 7 option exercises and 5 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 28 sales worth about $5.5M.
The largest open-market sale was 58,356 shares of KALV at an average $15.01 on February 14, 2024, about $876K. Twelve months later KALV was down 34%.
1 of the 7 sales since April 2023 was made under a Rule 10b5-1 trading plan; the other 6 were not.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 24,888 | $14.11 | $351,289.14 | -10.5% | -13.9% | -22.4% | |
| Feb 14, 2024 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell | 58,356 | $15.01 | $875,882.71 | -24.3% | -13.3% | -33.8% | |
| Feb 1, 2024 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell | 10,000 | $16.22 | $162,198.44 | -7.8% | -22.6% | -43.4% | |
| Dec 27, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell10b5-1 | 30,000 | $12.02 | $360,453.00 | -19.0% | -7.7% | -26.7% | |
| Nov 20, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 14,807 | $8.23 | $121,851.25 | -8.6% | +68.1% | +10.2% | |
| Aug 18, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 14,876 | $10.73 | $159,601.63 | -9.2% | -29.4% | +11.3% | |
| May 18, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 5,627 | $10.14 | $57,082.54 | -4.2% | +3.7% | +14.6% | |
| Feb 17, 2023 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 6,700 | $7.66 | $51,322.00 | -5.2% | +28.1% | +83.0% | |
| Nov 18, 2022 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sale+OE | 1,785 | $5.44 | $9,710.40 | -1.5% | +49.7% | +59.5% | |
| Sep 2, 2022 | KALV Kalvista Pharmaceuticals, Inc. | CEO | Sell | 1,320 | $17.01 | $22,457.69 | -1.2% | -66.9% | -34.0% |